Zusammenfassung
Gerade vor dem Hintergrund der demografischen Situation einer immer älter werdenden
Gesellschaft ist es von großem Interesse, die Auswirkungen eines Testosteronmangels
bei älteren Männern und dessen Therapie intensiv zu beforschen. Denn mit der Therapie
lässt sich dem Schwund der Muskel- und Knochenmasse, der Anämie, der nachlassenden
Potenz wie auch der zunehmenden Adipositas erfolgreich entgegen wirken. Dies wiederum
trägt dazu bei, die Selbstständigkeit der Betroffenen zu erhalten und eine potenzielle
Betreuungs- und Pflegebedürftigkeit zu verhindern. Diskutiert werden auch positive
Auswirkungen auf das Herz-Kreislaufsystem. Das Risiko bezüglich der Indikation oder
Progression eines Prostatakarzinoms scheint nach aktueller Studienlage eher gering
zu sein. Dennoch ist die Testosteronsubstitution beim Late-onset-Hypogonadismus keinesfalls
als Standard und abgesichert anzusehen, denn die Erfahrungen mit der Hormontherapie
beruhen überwiegend auf vergleichsweise kleinen Studien mit kurzen Beobachtungsintervallen.
Daher ist es von besonderer Bedeutung, Nutzen und Risiko einer Testosteronsubstitution
genau abzuwägen und Kontraindikationen zu beachten.
Summary
Against the background of the demographic situation in a progressively ageing society
it is of particular interest to closely investigate the effects of testosterone deficiency
in the elderly man, and its treatment. For this form of therapy can successfully counteract
the loss of muscle mass and bone substance, anaemia, declining virility and increasing
obesity. This in turn helps to preserve the independence of this group and prevent
a potential need for nursing care. A possible positive impact on the cardiovascular
system is also under discussion. Current data indicate that the risk concerning the
indication or progression of prostate carcinoma is low. Nevertheless, testosterone
replacement in late-onset hypogonadism must not be considered standard and confirmed
treatment, since most experience with hormone therapy has been gained in relatively
small studies involving short periods of observation. It is thus of particular importance
to weigh up the benefits and risks of testosterone substitution and to take account
of contraindications.
Key Words
late-onset hypogonadism - testosterone substitution - prostate gland
Literatur
- 1
Baumgartner RN, Waters DL, Gallagher D. et al. .
Predictors of skeletal muscle mass in elderly men and women.
Mech Age Develop.
1999;
107
123-136
- 2
Bhasin S, Bagatell CJ, Bremner WJ. et al. .
Issues in testosterone replacement in older men.
J Clin Endocrinol Metab.
1998;
83
3435-3448
- 3
Bhasin S, Buckwalter JG.
Testosterone supplementation in older men: a rationale idea whose time has not yet
come.
J Androl.
2001;
22
718-731
- 4
Bilezikian JP.
Osteoporosis in men.
J Clin Endocrinol Metab.
1999;
84
3431-3434
- 5
Boyanov MA, Boneva Z, Christov VG.
Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial
androgen deficiency.
The Aging Male.
2003;
6
1-7
- 6
Breuer B, Trungold S, Martucci C. et al. .
Relationship of sex hormone levels to dependence in activities of daily living in
the frail elderly.
Maturitas.
2001;
39
147-159
- 7
Bross R, Javanbahkit M, Bhasin S.
Anabolic interventions for aging-associated sarcopenia.
J Clin Endocrinol Metab.
1999;
84
3420-3430
- 8
Feldman HA.
Age trends in the levels of serum testosterone and other hormones in the middle-aged
men: longitudinal results from the Massachusetts Male Aging Study.
J Clin Endocrinol Metab.
2002;
87
589-598
- 9
Haffner SM, Shaten J, Stern MP. et al. .
Low levels of sex hormone-binding globulin and testosterone predict the development
of non-insulin-dependent diabetes mellitus in men.
Am J Epidemiol.
1996;
143
889-897
- 10
Hajjar RR, Kaiser FE, Morley JE.
Outcome of long-term testosterone replacement in older hypogonadal males: a retrospective
analysis.
J Clin Endocrinol Metab.
1997;
82
3793-3796
- 11
Hak AE, Wittemann JC, De Jong FH. et al. .
Low levels of endogenous androgens increase the risk of atherosclerosis in elderly
men: the Rotterdam study.
J Clin Endocrinol Metab.
2002;
87
3632-3639
- 12
International Prostate Health Council Study Group .
Estrogens and prostatic disease.
Prostate.
2000;
45
87-100
- 13
Lamberts SWJ, van den Beld AW, van der Lely AJ.
The endocrinology of aging.
Science.
1998;
278
419-424
- 14
Marin P, Holmäng S, Gustafsson C. et al. .
Androgen treatment of abdominally obese men.
Obes Res.
1993;
1
245-251
- 15
Morales A, Lunenfeld B.
Investigation, treatment and monitoring of late-onset hypogonadism in males.
Ageing Male.
2002;
5
74-86
- 16
Morley JE, Perry HM, Kaiser FE. et al. .
Effects of testosterone replacement therapy in old hypogonadal males: a preliminary
study.
J Am Geriatr Soc.
1993;
41
149-152
- 17
Orwoll ES, Klein RF.
Osteoporosis in men.
Endocr Rev.
1995;
16
87-116
- 18
Rhoden EL, Morgentaler A.
Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer:
results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
J Urol.
2003;
170
2348-2351
- 19
Rolf C, von S Eckardstein, Koken U, Nieschlag E.
Testosterone substitution of hypogonadal men prevents the age-dependent increases
in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional
study.
Eur J Endocrinol.
2002;
146
505-511
- 20
Shabsigh R, Kaufman JM, Steidle JC, Padma-Nathan H.
Randomised study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal
men with erectile dysfunction who do not respond to sildenafil alone.
J Urol.
2004;
172
658-663
- 21
Slater S, Oliver RTD.
Testosterone: its role in development of prostate cancer and potential risk from use
as a hormone replacement therapy.
Drugs and Aging.
2000;
17
431-439
- 22
Snyder PJ, Peachey H, Hannoush P. et al. .
Effect of testosterone treatment on bone mineral density in men over 65 years of age.
J Clin Endocrinol Metab.
1999;
84
1966-1972
- 23
Stellato RK, Feldman HA, Hamdy NAT. et al. .
Testosterone, sex hormone-binding globulin and the development of type 2 diabetes
in middle-aged men: prospective results from the Massachusetts male aging study.
Diabetes Care.
2000;
23
490-494
- 24
Swerdloff RS, Wang C, Cunningham GR. et al. .
Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
J Clin Endocrinol Metab.
2000;
85
4500-4510
- 25
Urban RJ, Bodenburg YH, Gilkison C. et al. .
Testosterone administration to elderly men increases skeletal muscle strength and
protein synthesis.
Am J Physiol.
1995;
269
E820-E826
Anschrift für die Verfasser
Prof. Dr. F. Jockenhövel
Medizinische Klinik, Evangelisches Krankenhaus Herne
Wiescherstr. 24
44623 Herne
